CRISPR therapy shows promising results in sickle cell patients, FDA decision pending.

Vertex and CRISPR Therapeutics have announced that the first CRISPR therapy is up for FDA approval, marking a significant milestone in the development of gene-altering medicines. The therapy uses CRISPR gene editing technology to treat sickle cell disease, and a decision on its approval is expected in December.